Strategic Financial Concepts LLC Makes New Investment in Mesoblast Limited (NASDAQ:MESO)

Strategic Financial Concepts LLC acquired a new position in shares of Mesoblast Limited (NASDAQ:MESO) during the fourth quarter, HoldingsChannel reports. The firm acquired 138,600 shares of the company’s stock, valued at approximately $2,744,000.

Other large investors also recently made changes to their positions in the company. Jane Street Group LLC raised its position in Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after acquiring an additional 26,959 shares in the last quarter. Clayton Financial Group LLC acquired a new position in shares of Mesoblast during the 4th quarter worth about $275,000. Ballentine Partners LLC bought a new stake in shares of Mesoblast in the 4th quarter valued at about $222,000. Signaturefd LLC lifted its stake in Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after purchasing an additional 3,099 shares during the last quarter. Finally, Creative Planning bought a new position in Mesoblast during the third quarter worth about $147,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Trading Down 2.9 %

Shares of NASDAQ MESO opened at $17.90 on Tuesday. The business’s 50 day moving average is $17.32 and its 200-day moving average is $11.52. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. Mesoblast Limited has a 1-year low of $1.91 and a 1-year high of $22.00.

Analyst Ratings Changes

Several analysts have issued reports on MESO shares. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $24.00 price objective (up from $15.00) on shares of Mesoblast in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.